Navigation Links
MAP Pharmaceuticals Submits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug
Date:5/26/2011

MOUNTAIN VIEW, Calif., May 26, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for LEVADEX® orally inhaled migraine drug for the potential acute treatment of migraine in adults. According to the National Headache Foundation, approximately 30 million people in the United States suffer from migraine, a debilitating neurological disorder. Common symptoms of migraine include recurrent headaches, nausea, phonophobia (sensitivity to sound) and photophobia (sensitivity to light).

"This NDA submission marks a major corporate milestone for MAP Pharmaceuticals and brings us one step closer to our goal of providing the underserved migraine patient population with a potential new treatment option," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals. "Our comprehensive development program evaluated LEVADEX in approximately 1,000 patients for up to one year, treating nearly 10,000 migraines. If approved by the FDA, LEVADEX could potentially provide a new treatment option for migraine sufferers, including the millions of patients whose migraines are not well treated today."

The 505(b)(2) NDA submission is based on a comprehensive development program for LEVADEX, and includes efficacy and safety data from the Phase 3 FREEDOM-301 clinical trial that has been presented at scientific conferences and was recently published in Headache: The Journal of Head and Face Pain. In the FREEDOM-301 trial, patients self-administered LEVADEX at home using the Company's proprietary TEMPO® inhaler. LEVADEX contains a novel formulation of dihydroergotamine (DHE).  Patients taking LEVADEX in this pivotal trial had statistically significant improvement at two hours compared to patients on placebo for all four c
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Watson Acquires Specifar Pharmaceuticals
2. Auxilium Pharmaceuticals, Inc. Updates Launch Progress of XIAPEX® in EU
3. BioMarin to Present at the UBS Global Specialty Pharmaceuticals Conference
4. Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
5. Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
6. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
7. Vanda Pharmaceuticals Reports First Quarter 2011 Results
8. MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
9. Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results
10. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
11. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... United States (PRWEB) September 16, 2014 ... Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies is ... This report focuses on the three principal types ... of research and development in cancer immunotherapy (which ... inhibitors, Therapeutic anticancer vaccines and Adoptive cellular immunotherapy. ...
(Date:9/15/2014)... very idea of fibers made of carbon nanotubes is neat, ... , The single-walled carbon nanotubes in new fibers created at ... a process designed by chemist Angel Mart and his colleagues. ... its results this month in the journal ACS Nano ... drawn together into a fiber. , Left to their own ...
(Date:9/15/2014)... DUBLIN , Sept. 15, 2014 Research ... "Whole Exome Sequencing Market by Product, by Services, by Technology, ... their offering. Whole Exome Sequencing (WES) is ... the genome, i.e. the exon. The exome, which is the ... of the total genome and is actually converted into proteins ...
(Date:9/15/2014)... , 15 de septiembre de 2014 La segunda ... a cabo del 12 al 18 de octubre. Como iniciativa ... y de sus compañías miembro s, la IPAW se ... mundial en torno a la colección de fuentes de plasma ... plasma al salvar y mejorar las vidas , Aumento ...
Breaking Biology Technology:Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5Rice rolls 'neat' nanotube fibers 2Rice rolls 'neat' nanotube fibers 3Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 3La International Plasma Awareness Week será una celebración para los donantes 2La International Plasma Awareness Week será una celebración para los donantes 3
... Md., Aug. 18, 2011 The Plasma Protein Therapeutics ... Medicaid Services (CMS) take necessary steps to improve drug ... At last week,s Advisory Panel on Ambulatory ... continued failure by CMS to remove hospitals that purchase ...
... Aug. 18, 2011 Reportlinker.com announces that ... in its catalogue: Global ... http://www.reportlinker.com/p0588171/Global-Genetic-Testing-Market-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics In a ... represents a highly attractive segment. Genetic testing ...
... 2011 Poplar Healthcare, a leading laboratory services company, ... the existing entities known as GI Pathology, D-PATH Dermatopathology ... expand," remarks William McDowell, CEO of Poplar Healthcare, "we ... brand to which our individual companies could belong, while ...
Cached Biology Technology:PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies 2PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies 3PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies 4Global Genetic Testing Market Analysis 2Global Genetic Testing Market Analysis 3Poplar Healthcare Forms Parent Company, Launches New Web Site 2
(Date:9/15/2014)... as much as 170 tons, the blue whale is the ... living thing ever seen on Earth. So there,s no way ... larvae, which measure millimeters in length and tip the scales ... so fast, says L. Mahadevan, the Lola England de Valpine ... of Physics. , Using simple hydrodynamics, a team of ...
(Date:9/15/2014)... tip the balance between ridding the body of a ... a report appearing in The Journal of ... viruses cause chronic infections in roughly three-quarters of infected ... diseases including cirrhosis and cancer. A few patients successfully ... CD8 + T cells. The protective effects of ...
(Date:9/15/2014)... Calif. , Sept. 15, 2014  GENiSYSS, ... California , announces the public launch of ... very unique, patented product, combining room temperature, long-term ... the only company to make personal storage of ... Photo - http://photos.prnewswire.com/prnh/20140912/145664   Photo - ...
Breaking Biology News(10 mins):The science behind swimming 2The science behind swimming 3GENiSYSS Launches Website about Easy, Inexpensive Home DNA Storage for Everyone 2
... Ribbons of ultrathin graphene combined with polyurethane paint meant for ... according to scientists at Rice University. The Rice ... developed the compound to protect marine and airborne radars with ... The research was published this week in the ...
... causes diseases like Alzheimer,s, Parkinson,s and Creutzfeldt-Jakob disease. ... lead to the development of new composite materials ... tomorrow, and even make objects invisible. Researchers ... unexpected discovery about amyloid in an article published ...
... 2013Time-lapse movies of a cellular heaven and hell, a crane ... of muscle cells were recognized with the top three awards ... Cell Biology Video Contest for 2013. The awards were ... ASCB Annual Meeting, Sunday , Dec. 14, in New Orleans. ...
Cached Biology News:Graphene nanoribbons an ice-melting coat for radar 2Graphene nanoribbons an ice-melting coat for radar 3Alzheimer substance may be the nanomaterial of tomorrow 2Celldance 2013 video awards, the 'Cell Oscars,' roll out tiny red carpet 2Celldance 2013 video awards, the 'Cell Oscars,' roll out tiny red carpet 3
...
Mouse monoclonal antibody raised against a partial recombinant VRK2. NCBI Entrez Gene ID = VRK2...
Mouse monoclonal antibody raised against a partial recombinant L3MBTL2. NCBI Entrez Gene ID = L3MBTL2...
Mouse polyclonal antibody to BAG2 - BCL2-associated athanogene 2...
Biology Products: